Naphthyridine derivatives and pharmaceutical compositions thereof
    1.
    发明授权
    Naphthyridine derivatives and pharmaceutical compositions thereof 失效
    萘啶衍生物及其药物组合物

    公开(公告)号:US5817670A

    公开(公告)日:1998-10-06

    申请号:US776295

    申请日:1997-01-30

    IPC分类号: C07D471/04 A61K31/435

    CPC分类号: C07D471/04

    摘要: 1,8-Naphthyridine derivatives represented by the following general formula (I), salts thereof, hydrates thereof and solvates thereof. ##STR1## They have an activity to inhibit type IV phosphodiesterase and are useful as agents for the prevention and treatment of respiratory diseases, inflammatory diseases accompanying organ transplantation, systemic or local arthropathy, proliferative diseases, micturition-related diseases and diseases in which tumor necrosis factor (TNF) and other cytokine (IL-1, IL-6 or the like) are concerned.

    摘要翻译: PCT No.PCT / JP95 / 01700 Sec。 371日期1997年1月30日 102(e)日期1997年1月30日PCT 1995年8月28日PCT公布。 公开号WO96 / 06843 日期:1993年3月7日,由以下通式(I)表示的8-萘啶衍生物,其盐,其水合物和溶剂化物。 可用作预防和治疗呼吸系统疾病,伴随器官移植的炎性疾病,全身或局部关节病,增殖性疾病,排尿相关疾病和肿瘤坏死因子(TNF)等细胞因子(TNF-α) IL-1,IL-6等)。

    Crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
    5.
    发明授权
    Crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative 失效
    杂环双(膦酸)衍生物的一水合物晶体

    公开(公告)号:US5480875A

    公开(公告)日:1996-01-02

    申请号:US360701

    申请日:1994-12-21

    CPC分类号: C07F9/6561

    摘要: Crystal D or E of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane -1,1-bis(phosphonic acid) monohydrate having specified lattice spacing and relative intensity in the powder X-ray diffraction spectrum obtained by using Cu-K.alpha. radiation and a dehydration peak temperature of 135.degree. to 149.degree. C. or 160.degree. to 170.degree. C. according to TG-DSC thermogravimetric analysis; and to a solid pharmaceutical preparation containing the same. The crystals are useful for producing a stable solid pharmaceutical preparation of the above compound which has an excellent drug efficacy for diseases wherein increased bone resorption participates, such as osteoporosis.

    摘要翻译: PCT No.PCT / JP93 / 00821 Sec。 371日期1994年12月21日 102(e)日期1994年12月21日PCT提交1993年6月18日PCT公布。 出版物WO94 / 00462 日期:1994年1月6日。具有指定晶格间距的1-羟基-2-(咪唑并[1,2-a]吡啶-3-基)乙烷-1,1-双(膦酸)一水合物的晶体D或E, 根据TG-DSC热重分析,通过使用Cu-Kα辐射获得的粉末X射线衍射光谱中的相对强度和135℃至149℃或160℃至170℃的脱水峰温度; 和含有该制剂的固体药物制剂。 所述晶体可用于制备上述化合物的稳定的固体药物制剂,其对增加的骨吸收参与的疾病如骨质疏松症具有优异的药物功效。

    Nitrogen-containing heterocyclic compounds
    7.
    发明授权
    Nitrogen-containing heterocyclic compounds 失效
    含氮杂环化合物

    公开(公告)号:US4251533A

    公开(公告)日:1981-02-17

    申请号:US67918

    申请日:1979-08-20

    摘要: Novel nitrogen-containing heterocyclic compounds shown by the formula ##STR1## wherein one of R.sub.1 and R.sub.2 represents a lower alkyl group, a phenyl group, a halophenyl group, or a lower alkoxyphenyl group and the other of them represents a hydrogen atom, a lower alkyl group, or a phenyl lower alkyl group; said R.sub.1 and R.sub.2 may combine with each other to form a trimethylene group or a tetramethylene group; R.sub.3 represents a hydrogen atom, a lower alkyl group, a phenyl group, or a phenyl lower alkyl group; X represents an oxygen atom, a sulfur atom, an imino group, or a group shown by ##STR2## wherein m represents 1 or 2 and R.sub.4 represents a lower alkyl group, a hydroxy lower alkyl group, a cycloalkyl group or a phenyl lower alkyl group; and Y represents an ethylene group which may be substituted by lower alkyl group, a trimethylene group, a tetramethylene group, a vinylene group which may be substituted by a lower alkyl group, or ##STR3## wherein R.sub.5 represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, or a phenyl group; said X is the group shown by ##STR4## when one of said R.sub.1 and R.sub.2 is a lower alkyl group and the other is a hydrogen atom, and said Y is an ethylene group, 1/7and the pharmacologically acceptable non-toxic salts thereof.The compounds described above are strong analgesic anti-inflammatory agents.

    摘要翻译: 式中,R 1和R 2中的一个表示低级烷基,苯基,卤代苯基或低级烷氧基苯基,另一方表示氢原子,低级 烷基或苯基低级烷基; 所述R1和R2可以相互结合形成三亚甲基或四亚甲基; R3表示氢原子,低级烷基,苯基或苯基低级烷基; X表示氧原子,硫原子,亚氨基或由下式表示的基团,其中m表示1或2,R4表示低级烷基,羟基低级烷基,环烷基或苯基低级烷基 组; Y表示可以被低级烷基,三亚甲基,四亚甲基,可被低级烷基取代的亚乙烯基取代的亚乙基,或者R5表示氢原子的低级烷基 基,三氟甲基或苯基; 当所述R 1和R 2中的一个为低级烷基且另一个为氢原子,所述Y为亚乙基时,X为所示的基团,其药理学上可接受的无毒性盐 。 上述化合物是强镇痛抗炎剂。

    1-Oxo-1,2-dihydroisoquinoline derivatives
    8.
    发明授权
    1-Oxo-1,2-dihydroisoquinoline derivatives 失效
    1-氧代-1,2-二氢异喹啉衍生物

    公开(公告)号:US4198512A

    公开(公告)日:1980-04-15

    申请号:US925217

    申请日:1978-07-17

    CPC分类号: C07D217/24

    摘要: Novel 1-oxo-1,2-dihydroisoquinoline compounds of the formula ##STR1## wherein R.sub.1 represents a lower alkyl group or a phenyl lower alkyl group; R.sub.2 represents a lower alkyl group; R.sub.3 represents a hydrogen atom, a lower alkanoyl group, a lower alkyl group or a hydroxy lower alkyl group; and n is 0, 1 or 2 and the pharmacologically acceptable non-toxic salts thereof.The compounds of this invention are strong analgesic anti-inflammatory agents.

    摘要翻译: 新颖的式Ⅰ-1-氧代-1,2-二氢异喹啉化合物,其中R1代表低级烷基或苯基低级烷基; R2表示低级烷基; R3表示氢原子,低级烷酰基,低级烷基或羟基低级烷基; 和n为0,1或2及其药理学上可接受的无毒盐。 本发明的化合物是强镇痛抗炎剂。